Open access
Sep 2026
Pseudoprogression in neoadjuvant immunotherapy for resectable NSCLC: a PET–CT-based study
Background Neoadjuvant chemoimmunotherapy is standard for resectable non-small-cell lung cancer (NSCLC) but response assessment is challenging due to pseudoprogression, which may lead to unnecessary cancellation of surgery. We characterized pseudoprogression and developed a clinical strategy to distinguish it from true...
Y. Pan, J. Chen, H. Lin et al.
· ESMO Open · 0 citations